Disease-modifying therapies and infectious risks in multiple sclerosis

Area of Science:

• Neuroimmunology
• Infectious Disease Management in Autoimmune Disorders

Background:

• Immunomodulatory and immunosuppressive therapies for multiple sclerosis (MS) are linked to a higher incidence of infections.
• Managing these treatment-associated infections presents a significant challenge in routine clinical practice for MS patients.
• The growing array of available MS drugs necessitates comprehensive understanding of their infection risks and management protocols.

Purpose of the Study:

• To review the mechanisms of action for current multiple sclerosis drugs.
• To correlate drug mechanisms with known infection risks associated with each therapy.
• To outline strategies for minimizing and managing treatment-related infections in MS patients.

Main Methods:

• Literature review of immunomodulatory and immunosuppressive treatments for multiple sclerosis.
• Analysis of drug mechanisms of action in relation to infectious complications.
• Synthesis of current knowledge on drug-specific infection risks and risk-mitigation strategies.

Main Results:

• Different MS therapies possess distinct mechanisms that influence susceptibility to specific infections.
• Understanding these drug-specific risks is crucial for proactive management.
• Individualized risk stratification is essential for selecting and monitoring MS therapies.

Conclusions:

• An interdisciplinary approach is vital for evaluating and managing infectious events in patients undergoing MS treatment.
• Personalized assessment of infection risk is necessary before, during, and after immunotherapy for multiple sclerosis.
• Knowledge of drug actions and associated infectious risks informs safer and more effective MS treatment strategies.